| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Multiple targets involved in cell proliferation, apoptosis induction, and gut microbiota modulation.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Kansuiphorin C exhibits potent cytotoxic activity against various cancer cell lines by inducing apoptosis and disrupting cell proliferation pathways. The compound's mechanism of action involves regulation of cell cycle progression and activation of apoptotic signaling cascades. Kansuiphorin C has been shown to modulate gut microbiota composition in vitro, increasing the abundance of Lactobacillus and decreasing the abundance of Helicobacter, which are involved in carbohydrate and amino acid metabolism. These effects on gut microbiota may contribute to the compound's ability to ameliorate malignant ascites, a serious complication of advanced cancer.
|
| ln Vivo |
In vivo studies have demonstrated that Kansuiphorin C ameliorates malignant ascites by modulating gut microbiota and related metabolic functions. The compound increases the abundance of Lactobacillus and decreases the abundance of Helicobacter in the gut microbiome, which may contribute to its inhibitory effects on malignant ascites. These changes in gut microbiota composition are associated with alterations in carbohydrate and amino acid metabolism. The compound's cytotoxic and anti-tumor activities have also been demonstrated in various in vivo cancer models, where it induces apoptosis and inhibits tumor growth. These findings support the potential of Kansuiphorin C as a lead compound for developing novel anticancer therapies.
|
| Enzyme Assay |
Cytotoxicity assays are performed using various cancer cell lines including human cancer cells. Cells are seeded in 96-well plates and treated with serial dilutions of Kansuiphorin C for 48-72 hours. Cell viability is assessed using MTT, CCK-8, or SRB assays, and IC50 values are calculated from dose-response curves. Apoptosis induction is evaluated by flow cytometry using Annexin V/PI staining, caspase activity assays, or detection of cleaved PARP by Western blotting. Cell cycle analysis is performed by flow cytometry following propidium iodide staining. Gut microbiota modulation is assessed using in vitro culture systems with representative bacterial strains.
|
| Cell Assay |
Cellular assays for Kansuiphorin C typically involve culturing cancer cell lines (such as HeLa, MCF-7, A549, or other relevant lines) and treating them with the compound at various concentrations. Cell proliferation is assessed using MTT or CCK-8 assays. Apoptosis is evaluated using Annexin V/PI staining, caspase-3/7 activity assays, or Western blotting for apoptotic markers (cleaved caspase-3, cleaved PARP, Bcl-2, Bax). Cell cycle distribution is analyzed by flow cytometry after propidium iodide staining. For studies of gut microbiota effects, co-culture systems with intestinal epithelial cells and bacterial strains are used to assess the compound's effects on bacterial growth and metabolic activity.
|
| Animal Protocol |
In vivo efficacy of Kansuiphorin C is evaluated in mouse models of malignant ascites and cancer. For malignant ascites studies, mice are injected intraperitoneally with cancer cells to induce ascites formation, and then treated with Kansuiphorin C via oral or intraperitoneal administration. Ascites volume is measured, and survival is monitored. Gut microbiota composition is analyzed by 16S rRNA sequencing of fecal samples. For tumor growth studies, xenograft mouse models are used where tumor-bearing mice are treated with the compound, and tumor volume is measured over time. Histopathological examination of tumors and other tissues is performed to assess treatment effects.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Kansuiphorin C have been studied to support its use as a lead compound for drug development. The compound's molecular weight of 478.58 and lipophilic nature influence its absorption, distribution, metabolism, and excretion (ADME) characteristics. Key PK parameters including half-life, clearance, volume of distribution, and bioavailability are determined using LC-MS/MS analysis of plasma and tissue samples following administration. The compound's complex structure and natural product origin present both opportunities and challenges for drug development, with efforts focused on improving its pharmacokinetic properties through medicinal chemistry optimization.
|
| Toxicity/Toxicokinetics |
Toxicological evaluation of Kansuiphorin C is typically conducted in parallel with efficacy studies in animal models. Standard toxicology assessments include acute toxicity studies to determine the maximum tolerated dose, observation of clinical signs and body weight changes, and histopathological examination of major organs following repeated dosing. The compound's cytotoxic activity against cancer cells is associated with potential toxicity to normal cells, and the therapeutic index is carefully evaluated. As a natural product with complex chemistry, the compound's safety profile is established to define the therapeutic window for research and development applications.
|
| References | |
| Additional Infomation |
Reports indicate that plants in the Euphorbia genus contain [(1S,4S,5R,6R,9R,10R,12R,14R)-4-acetoxy-5-hydroxy-3,7,11,11,14-pentamethyl-15-oxo-6-tetracyclo[7.5.1.01,5.010,12]pentadecano-2,7-dienyl]benzoate, and related data have been reported.
Kansuiphorin C is a natural product diterpenoid with potent cytotoxic and anti-tumor activities, as well as the ability to modulate gut microbiota and ameliorate malignant ascites. The compound is isolated from Euphorbia kansui and has been studied for its potential as a lead compound for developing novel anticancer and anti-inflammatory agents. Its mechanism of action involves induction of apoptosis, disruption of cell proliferation pathways, and modulation of gut microbiota composition and metabolic function. The compound is not approved for clinical use and is intended for laboratory research purposes only. Its complex chemical structure and diverse biological activities make it a valuable tool for natural product drug discovery research. |
| Molecular Formula |
C29H34O6
|
|---|---|
| Molecular Weight |
478.585
|
| Exact Mass |
478.235
|
| Elemental Analysis |
C, 72.78 H, 7.16 O, 20.06
|
| CAS # |
133898-77-8
|
| PubChem CID |
155487900
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
606.7±44.0 °C at 760 mmHg
|
| Flash Point |
196.8±21.9 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.597
|
| LogP |
6.22
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
35
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@@H]1C[C@@H]2[C@@H](C2(C)C)[C@H]3C=C([C@H]([C@]4([C@@]1(C3=O)C=C([C@@H]4OC(=O)C)C)O)OC(=O)C5=CC=CC=C5)C
|
| InChi Key |
IDDLQFSLFADOOA-ISFUUBDKSA-N
|
| InChi Code |
InChI=1S/C29H34O6/c1-15-12-20-22-21(27(22,5)6)13-17(3)28(23(20)31)14-16(2)25(34-18(4)30)29(28,33)24(15)35-26(32)19-10-8-7-9-11-19/h7-12,14,17,20-22,24-25,33H,13H2,1-6H3/t17-,20-,21-,22+,24-,25+,28+,29+/m1/s1
|
| Chemical Name |
(1aR,2R,5R,5aR,6S,8aS,9R,10aR)-6-(Acetyloxy)-5-(benzoyloxy)-1a,2,5,5a,6,9,10,10a-octahydro-5a-hydroxy-1,1,4,7,9-pentamethyl-1H-2,8a-methanocyclopenta[a]cyclopropa[e]cyclodecen-11-one
|
| Synonyms |
Kansuiphorin C
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~208.95 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0895 mL | 10.4474 mL | 20.8947 mL | |
| 5 mM | 0.4179 mL | 2.0895 mL | 4.1789 mL | |
| 10 mM | 0.2089 mL | 1.0447 mL | 2.0895 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
